HZNP
Income statement / Annual
Last year (2022), Horizon Therapeutics Public Limited Company's total revenue was $3.63 B,
an increase of 12.48% from the previous year.
In 2022, Horizon Therapeutics Public Limited Company's net income was $521.48 M.
See Horizon Therapeutics Public Limited Company’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$3.63 B
|
$3.23 B
|
$2.20 B
|
$1.30 B
|
$1.21 B
|
$1.06 B
|
$981.12 M
|
$757.04 M
|
$296.96 M
|
$74.02 M
|
| Cost of Revenue |
$920.20 M |
$794.51 M |
$532.70 M |
$362.18 M |
$422.32 M |
$546.28 M |
$393.27 M |
$219.50 M |
$78.75 M |
$14.63 M |
| Gross Profit |
$2.71 B |
$2.43 B |
$1.67 B |
$937.85 M |
$785.25 M |
$509.96 M |
$587.85 M |
$537.54 M |
$218.20 M |
$59.39 M |
| Gross Profit Ratio |
0.75 |
0.75 |
0.76 |
0.72 |
0.65 |
0.48 |
0.6 |
0.71 |
0.73 |
0.8 |
| Research and Development
Expenses |
$437.96 M
|
$431.99 M
|
$209.36 M
|
$103.17 M
|
$82.76 M
|
$224.96 M
|
$60.71 M
|
$41.87 M
|
$17.46 M
|
$10.08 M
|
| General & Administrative
Expenses |
$1.54 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$287.94 M
|
$219.86 M
|
$88.96 M
|
$23.57 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$320.37 M
|
$220.44 M
|
$120.28 M
|
$68.60 M
|
| Selling, General &
Administrative Expenses |
$1.54 B
|
$1.45 B
|
$973.23 M
|
$697.11 M
|
$692.49 M
|
$677.36 M
|
$608.31 M
|
$440.31 M
|
$209.23 M
|
$92.16 M
|
| Other Expenses |
-$5.57 M |
$1.79 M |
$3.39 M |
-$944,000.00 |
$346,000.00 |
$588,000.00 |
$6.70 M |
-$10.29 M |
-$11.25 M |
$0.00 |
| Operating Expenses |
$1.98 B |
$1.88 B |
$1.18 B |
$800.28 M |
$775.25 M |
$902.33 M |
$669.02 M |
$482.17 M |
$226.69 M |
$102.25 M |
| Cost And Expenses |
$2.90 B |
$2.67 B |
$1.72 B |
$1.16 B |
$1.20 B |
$1.45 B |
$1.06 B |
$701.67 M |
$305.45 M |
$116.87 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$83.71 M |
$81.06 M |
$59.62 M |
$87.09 M |
$121.69 M |
$126.52 M |
$86.61 M |
$69.90 M |
$23.83 M |
$39.18 M |
| Depreciation &
Amortization |
$497.25 M
|
$365.91 M
|
$277.96 M
|
$247.18 M
|
$275.73 M
|
$283.42 M
|
$221.84 M
|
$138.34 M
|
$34.01 M
|
$9.31 M
|
| EBITDA |
$1.11 B
|
$909.04 M
|
$767.98 M
|
$373.79 M
|
$286.08 M
|
-$108.37 M
|
$147.37 M
|
$55.37 M
|
-$8.49 M
|
-$42.85 M
|
| EBITDA Ratio |
0.31 |
0.28 |
0.35 |
0.29 |
0.24 |
-0.1 |
0.15 |
0.24 |
0.05 |
-0.45 |
| Operating Income Ratio
|
0.17
|
0.17
|
0.22
|
0.1
|
0
|
-0.37
|
-0.15
|
0.07
|
-0.03
|
-0.58
|
| Total Other
Income/Expenses Net |
-$90.48 M
|
-$80.30 M
|
-$88.38 M
|
-$146.84 M
|
-$121.54 M
|
-$120.91 M
|
-$80.92 M
|
-$188.08 M
|
-$261.20 M
|
-$107.27 M
|
| Income Before Tax |
$526.94 M |
$462.83 M |
$401.65 M |
-$20.22 M |
-$119.15 M |
-$513.28 M |
-$228.09 M |
-$132.71 M |
-$269.69 M |
-$150.13 M |
| Income Before Tax Ratio
|
0.15
|
0.14
|
0.18
|
-0.02
|
-0.1
|
-0.49
|
-0.23
|
-0.18
|
-0.91
|
-2.03
|
| Income Tax Expense |
$5.45 M |
-$71.66 M |
$11.85 M |
-$593.24 M |
-$44.96 M |
-$102.75 M |
-$61.25 M |
-$172.24 M |
-$6.08 M |
-$1.12 M |
| Net Income |
$521.48 M |
$534.49 M |
$389.80 M |
$573.02 M |
-$74.19 M |
-$410.53 M |
-$166.83 M |
$39.53 M |
-$263.60 M |
-$149.01 M |
| Net Income Ratio |
0.14 |
0.17 |
0.18 |
0.44 |
-0.06 |
-0.39 |
-0.17 |
0.05 |
-0.89 |
-2.01 |
| EPS |
2.28 |
2.37 |
1.91 |
3.13 |
-0.45 |
-2.52 |
-1.04 |
0.27 |
-3.15 |
-2.34 |
| EPS Diluted |
2.22 |
2.27 |
1.81 |
2.9 |
-0.45 |
-2.52 |
-1.04 |
0.25 |
-3.15 |
-2.34 |
| Weighted Average Shares
Out |
$229.11 M
|
$225.55 M
|
$215.31 M
|
$205.22 M
|
$166.16 M
|
$163.12 M
|
$160.70 M
|
$148.79 M
|
$83.75 M
|
$63.66 M
|
| Weighted Average Shares
Out Diluted |
$235.24 M
|
$235.68 M
|
$215.31 M
|
$205.22 M
|
$166.16 M
|
$163.12 M
|
$160.70 M
|
$155.92 M
|
$83.75 M
|
$63.66 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
